The clinical data of patients were collected, including gender, age, and routine blood test results 2 weeks before EGFR-TKIs treatment. Patients who received EGFR-TKIs first-line treatment were followed up, and the follow-up content included the follow-up treatment effect, whether recurrence or ...
Subgroup analyses were conducted, focusing exclusively on data from distinct patient demographics. Small-study effects were examined using funnel plots and statistically assessed with the Begg’s test. A two-sidedP < 0.05 was considered statistically significant [50]. Results Characteristics of the...
Simple column-free methods, e.g., Gentra Puregene Blood kit (QIAGEN GmbH, Germany), were recommended in cases in which sample material is limited, whereas other methods, e.g., QIAGEN FFPET kit (Formalin-Fixed Paraffin-Embedded Tissue kit; QIAGEN GmbH, Germany) can be used when material ...
Antigen-specific, HLA-A02 and HLA-A24-restricted cytotoxic T lymphocytes directed against an epitope of brachyury (WLLPGTSTV) or mucin-1 (MUC-1, KYHPMSEYAL), respectively, were generated and expanded as previously described from the blood of cancer patients.59,60 Cytotoxicity assay. Target ...
(BM) from non-small cell lung cancer (NSCLC), breast cancer, and melanoma, especially through targeted therapies focused on specific molecular drivers. These novel agents have improved outcomes by overcoming challenges posed by the blood-brain barrier (BBB) and resistance mechanisms, enabling more ...
This study included questionnaire surveys, physical measurements, and blood sampling. We deemed the mildly reduced eGFR to be 60–90 ml·min–1·(1.73 m2)–1. The relationship between changes in SUA levels and the eGFR was assessed. Results (1) During the 3-year follow-up period, 433 ...
Second, chemotherapy could affect EGFR mutation status, thus, the timing of tissue collection and peripheral blood collection matters the concordance rate. It is believed that Figure 3 | The summary operative receiver characteristic curve indicated high diagnostic accuracy (A, the area under summary ...
plus Lazcluze™ (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.1,2...
Despite the proven efficacy of erlotinib in vitro, it has been shown that human blood serum of healthy donors can donor-specifically dramatically abolish the cell growth rate inhibition by erlotinib, and this effect correlates with a decreased activity of ERK1/2 proteins and abolishment of drug-in...
Tumor molecular profiling upon disease progression enables investigations of the tumor evolution. Next-generation sequencing (NGS) of liquid biopsies constitutes a noninvasive readily available source of tumor molecular information. In this study, 124 pl